MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,084K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Atm offering, net of offering co...
Prepaid expense and other assets
Stock-based compensation
Others
Negative Cash Flow Breakdown
Change in fair value of warrant ...
Net loss
Cash used in investments
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents at beginning of period
-
-
1,443
-
Net loss
-1,430
360
-5,890
-23,092
Depreciation and amortization expense
63
42
28
-
Amortization of operating right of use assets
102
58
15
-
Warrant issuance costs related to alvogen termination
-
0
0
0
Stock-based compensation
151
81
68
79
Convertible note default penalty
-
0
0
0
Provision (recovery) for expected credit losses
28
40
-
-
Common stock issued in exchange for services
-
1
450
150
Change in fair value of warrant liabilities
-3,538
-3,555
4,963
3,518
Change in fair value of convertible promissory notes
0
-4,093
8,032
-
Depreciation expense
-
-
-
0
Loss on convertible note conversions
0
-1,962
-772
-3,467
Insurance loan payable
-
-
0
0
Gain on exercise of warrant liabilities
-
0
5,369
-
Loss on issuance of registered direct common stock
0
0
-1
-729
Loss on consideration shares and warrants
0
0
0
-1,277
Change in fair value of convertible note payable
-
-
-
6,530
Loss on equity method investments
2
-35
-
-
Expense for debt issuance costs due to fair value election on anson notes
0
0
0
350
Prepaid expense and other assets
-420
-451
-227
-187
Account receivable
48
-36
-12
-
Accounts payable
129
13
601
-501
Operating lease liabilities
-102
-55
-63
-
Accrued expense and other liabilities
-68
913
-210
-202
Net cash used in operating activities
-4,295
-3,713
-2,891
-7,508
Business acquisition, net of cash acquired
-
-183
2,561
-
Cash used in investments
213
432
-
-
Net cash used in investing activities
-213
-249
-2,561
-
Proceeds from issuance of insurance loan
-
0
-225
452
Repayment of convertible note
-
0
0
0
Proceeds from anson convertible note, net
-
0
0
5,000
Repayment of insurance note
0
154
0
394
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs
-
0
0
0
Proceeds from liability classified warrants
-
3,087
0
-
Expense for debt issuance costs due to fair value election on anson notes
0
0
0
350
Atm offering, net of offering costs
3,424
1,641
3,739
1,012
Proceeds from issuance of common stock and warrants, net of issuance costs-Consideration Warrants
0
0
6,213
3,255
Proceeds from issuance of common stock and warrants, net of issuance costs-Warrants Other Than Consideration Warrants
0
0
0
0
Net cash provided by financing activities
3,424
4,575
9,726
8,975
Net increase (decrease) in cash and cash equivalents
-1,084
613
4,274
1,467
Cash and cash equivalents at beginning of year
7,797
1,443
-
-
Cash and cash equivalents at end of period
-
-
7,200
-
Cash and cash equivalents at end of year
6,713
7,797
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Atm offering, net of
offering costs
$3,424K
Net cash provided by
financing activities
$3,424K
Net increase
(decrease) in cash and cash...
-$1,084K
Canceled cashflow
$3,424K
Prepaid expense and
other assets
-$420K
Stock-based compensation
$151K
Accounts payable
$129K
Amortization of operating
right of use assets
$102K
Depreciation and
amortization expense
$63K
Provision (recovery) for
expected credit losses
$28K
Net cash used in
operating activities
-$4,295K
Canceled cashflow
$893K
Net cash used in
investing activities
-$213K
Change in fair value of
warrant liabilities
-$3,538K
Net loss
-$1,430K
Operating lease
liabilities
-$102K
Accrued expense and
other liabilities
-$68K
Account receivable
$48K
Loss on equity method
investments
$2K
Cash used in
investments
$213K
Buy us a coffee
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)